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The recent discovery of a gene responsible for a particular form
of hypercalciuric nephrolithiasis has created excitement because it
promises to shed light on mechanisms involved in both calcium
stone formation and renal epithelial function. The disease that I
will refer to here as X-linked hypercalciuric nephrolithiasis
(XLHN) has been the subject of some confusion owing to the fact
that it has been described over the past five years by different
groups using different names, all but one of them polysyllabic:
“X-linked recessive nephrolithiasis with renal failure” in North
America, “Dent’s disease” in the United Kingdom, “X-linked
recessive hypophosphatemic rickets” in Italy, and “low-molecular-
weight proteinuria with hypercalciuria and nephrocalcinosis” in
Japan. These syndromes differ in degree from each other, but
common themes include proximal tubular reabsorptive failure,
nephrolithiasis, nephrocalcinosis, progressive renal insufficiency,
and in some cases rickets. The fact of mutations in the same gene
in each of these syndromes has now established that they are
phenotypic variants of a single disease and not separate entities.
Clinical studies of these patients produced few clues as to the
pathophysiology of the condition, and the gene responsible for
this disease was identified through a positional cloning approach
rather than through the study of logical candidate genes. The gene
identified, CLCN5, was novel. Sequence homology suggested, and
expression studies confirmed, that the gene product was a mem-
ber of the CLC family of voltage-gated chloride channels. This
was a surprise, since it is not immediately clear how mutations in
such a chloride channel could explain the clinical findings in this
disease. The physiology of the gene product, designated CLC-5, is
at present only partly understood, and is the subject of active
research.
SYNDROMES OF X-LINKED HYPERCALCIURIC
NEPHROLITHIASIS
Four syndromes of X-linked hypercalciuric nephrolithiasis
(XLHN) were reported independently, but mutations in the
chloride channel gene CLCN5 have been identified in all four
syndromes, justifying the view that these together represent a
single disease. Table 1 summarizes the features of these syn-
dromes as originally described. An understanding of these reports
is valuable in that it emphasizes the range of phenotypes in this
disease, and as an effort to clarify the relationships among what
some might otherwise be tempted to consider as separate entities.
X-linked recessive nephrolithiasis
In 1991, we reported a disease among members of a single large
family from Watertown in northern New York State that affected
only males, and gave it the descriptive name “X-linked recessive
nephrolithiasis with renal failure” (XRN) (McKusick catalog no.
310468) [1]. The essential clinical features of this syndrome were
urinary solute wasting suggestive of proximal tubular dysfunction,
calcium nephrolithiasis, nephrocalcinosis, and progressive renal
failure. The disease presented with proteinuria and microscopic
hematuria, in some cases within the first year of life. Kidney stones
occurred as early as three to six years of age in some patients, in
others first occurred in adulthood, and were composed of calcium
oxalate, often with calcium phosphate as well. Progression to renal
failure occurred in many but not all patients at some time in adult
life [1]. All affected individuals were male; carrier females were
asymptomatic with only mild biochemical abnormalities detect-
able in the urine [2].
While we were unable to establish an underlying pathophysio-
logic mechanism, the pedigree established clearly that inheritance
was X-linked recessive (Fig. 1). There were no instances of
male-to-male transmission (among 11 sons of affected males).
Daughters of affected males were themselves clinically unaf-
fected, with no stones or renal insufficiency in any carrier female,
but 50% of their male offspring were affected [1]. Virtually all of
the carrier females had some degree of low-molecular-weight
proteinuria and about one-third of carrier females were hypercal-
ciuric [2].
One patient has maintained a functioning kidney transplant,
which is radiographically free of nephrocalcinosis after 12 years,
suggesting that the defect is intrinsic to the renal tubule and is not
systemic.
The original report of this family included several patients with
moderate renal insufficiency in whom calcium excretion was
normal [1], but with further study of a larger number of patients
it became clear that hypercalciuria was present in all affected
individuals if studied at a time when renal function was still
preserved [2]. The most consistent urinary abnormality of all,
however, was excessive excretion of low-molecular-weight (LMW)
proteins, in both affected males and carrier females. Moderate
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polyuria occurred in affected males only, from early in childhood.
Other abnormalities of renal tubular function, such as glycosuria,
aminoaciduria, phosphaturia, kaliuresis, or uricosuria, were found
variably [1, 2]. These are discussed in detail below.
Patients with XRN have now been reported in families from
Montreal [3], Calgary [4], and St. Petersburg, Florida [5]. In all
cases boys presented with hematuria, proteinuria (primarily
LMW), hypercalciuria, nephrocalcinosis or nephrolithiasis, and a
family history including, in each case, the maternal grandfather
with a similar history including stones and terminating in end-
stage renal failure [3–5]. Renal biopsy findings in these cases, as in
the original family with XRN, showed a nonspecific pattern of
tubular atrophy, interstitial fibrosis, and glomerular sclerosis. All
together, we have data on eleven families in North America with
this syndrome. These include one family in which a woman has
had recurrent nephrolithiasis and another woman has proteinuria
and glomerular sclerosis (unpublished observation). Of the 30
affected males represented in these eleven families, there is one
patient with rickets (P. Goodyer, personal communication).
Dent’s disease
In 1964, Dent and Friedman reported the cases of two unre-
lated English boys who on evaluation for childhood rickets were
found to have renal tubular dysfunction including tubular protein-
uria, aminoaciduria, phosphate wasting, and hypercalciuria, with a
normal ability to acidify the urine. They reported no occurrence of
kidney stones or renal failure, and no kidney problems or rickets
in any family members [6]. However, Oliver Wrong and col-
leagues have followed these and other patients over the succeed-
ing 30 years, and have established that stones, renal failure, and
mendelian inheritance are clearly features of what they have
named “Dent’s disease,” which they described briefly in an
abstract in 1990 [7], and subsequently reported fully [8].
The value of LMW proteinuria as a consistently detectable
abnormality in one of these syndromes was first reported by
Wrong, Norden, and Feest in Dent’s disease [7, 8]. Other renal
functional defects, and the progression to renal failure, are also
essentially indistinguishable from those found in XRN, and will be
discussed in detail below. In Dent’s disease there is also a marked
male predominance, although Wrong et al did describe historic
information about one woman who was known to have died in
renal failure at age 56 with nephrocalcinosis. In general, female
carriers with Dent’s disease are asymptomatic, although all have
low molecular-weight proteinuria, and half are hypercalciuric [8].
Urinary acidification was defective in some of their patients, but
they did not consider this to be a primary feature of the disease,
since in all cases it could be attributed to renal insufficiency or
nephrocalcinosis. The one feature of Dent’s disease that appeared
to distinguish it definitively from XRN was rickets or osteomala-
cia, which in five children was the presenting feature. Overall,
however, rickets was present in only a third of affected males with
Dent’s disease [8].
X-linked recessive hypophosphatemic rickets
The third related syndrome, X-linked recessive hypophos-
phatemic rickets, was initially described in a family in Genoa,
Italy. Five males in this family presented with rickets or osteoma-
lacia, hypophosphatemia, and a reduced renal threshold for
phosphate reabsorption, but a number of features were atypical of
X-linked dominant hypophosphatemic rickets (HYP). For exam-
ple, these patients had hypercalciuria, and high levels of 1,25-
dihydroxyvitamin D. In addition, they had proteinuria of up to 3
grams per day. Patients developed nephrocalcinosis, with progres-
sive renal failure in early adulthood [9, 10].
In additional contrast with findings expected in X-linked dom-
inant hypophosphatemic rickets, female carriers in this family
were not hypophosphatemic, and lacked any biochemical abnor-
malities other than hypercalciuria [10]. It is of interest that two of
the four hypercalciuric females had “mild symptoms of bone
disease,” though no further details were given [9]. No member of
this family, male or female, had hypokalemia or aminoaciduria.
The locus of the HYP gene at Xp22, on the telomeric end of the
short arm of the X chromosome, is known, and the gene has been
cloned [11]. Using genetic markers that flank the HYP locus, a
group headed by Prof. Giovanni Romeo excluded the HYP gene
from linkage with the disease in this family. Further studies
established definite linkage to the pericentromeric region at
Xp11.22 that is also linked to XRN and Dent’s disease [10]. A
second such family was recently identified in France in which the
four affected males all had symptomatic rickets, and in whom the
disease linked to the same chromosomal region [12]. Urinary
excretion of LMW proteins, not measured in the Italian report,
was excessive in the affected French males.
This clinical syndrome differs from XRN and Dent’s disease
only in degree, but is potentially instructive, particularly regarding
the occurrence and severity of rickets. It is interesting that both
families share the same mutation (Table 2).
Low-molecular-weight proteinuria with hypercalciuria and
nephrocalcinosis
Because of the annual urine-screening program performed on
school children in Japan since 1974, and more recently in pre-
school children as well, the entity of asymptomatic low molecular-
weight proteinuria had been recognized in the 1980s. Other
abnormalities found in these children included microscopic he-
maturia, glycosuria, aminoaciduria, and hypophosphatemia [13,
14]. Biopsy findings were most often normal or nearly so, though
a third of patients had evidence of tubular atrophy and glomerular
sclerosis. Murakami and Kawakami noted a tendency to short
stature in the older children, and some patients had a decreased
creatinine clearance [14]. All but one of the 58 patients in these
Table 1. Four syndromes of X-linked hypercalciuric nephrolithiasis
Syndrome XRN
Dent’s
disease
X-linked
rickets
LMW
proteinuria/
nephrocalcinosis
References [1–5] [8] [10,12] [16,17]
Location of
reports
U.S.A., Canada U.K. Italy, France Japan
LMW proteinuria 1 1 1 1
Hypercalciuria 1 1 1 1
Nephrocalcinosis 1 1 1 1
Calcium stones 1 1
Renal failure 1 1 1
Male
predominance 1 1 1 1
Rickets 1 1
CLCN5 mutations 1 1 1 1
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two reports were male. Isolated tubular proteinuria with hyper-
calciuria has also been reported in one boy in England [15], who
has now been found to have a mutation in CLCN5 (#14 on Table
2) [19].
Igarashi and colleagues from Tokyo were the first to report
hypercalciuria in association with this syndrome. They described
seven such children from six different families, all of whom had
nephrocalcinosis. Six of the seven were boys, and had hypercalci-
uria; the one girl did not. No mention was made of any evidence
for bone disease. Two boys had aminoaciduria, two had glycos-
uria, and all had a mild impairment in urinary concentration [16].
A subsequent report included clinical data on additional boys,
as well as molecular data to be described below [17]. Of these
eight Japanese boys with idiopathic LMW proteinuria, hypercal-
ciuria, and nephrocalcinosis, none was more than 14 years old,
and so it is not surprising that serum creatinine measurements
were normal in all [16, 17], or that the six measured creatinine
clearance rates were normal as well [17]. These children were
identified by screening rather than by symptomatic disease, and
thus the absence of symptomatic renal colic or rickets should not
be viewed as distinguishing these patients from patients with XRN
or Dent’s disease. Nevertheless, the presence of nephrocalcinosis
in boys as young as three or five years of age [16, 17] indicates
significant disease, in which the prognosis may be no milder than
that of patients in North America or Britain.
Other reports
The literature contains several other descriptions consistent
with XLHN. Only one of these reported families has been studied
for mutation in the CLCN5 gene. This is an Italian family in which
males developed hematuria, LMW proteinuria, hypercalciuria,
phosphaturia, high 1,25-dihydroxyvitamin D levels, impaired uri-
nary concentration, and progressive renal insufficiency [18]. This
family also had a mutation in CLCN5 [19]. Bone mineral density
was reduced, but growth was normal and clinical rickets was
absent [18].
Buckalew et al reported a large (64-member) kindred in which
clinical features included hypercalciuria, nephrocalcinosis, neph-
rolithiasis, proteinuria with prominent LMW excretion, aminoaci-
duria, polyuria, and varying degrees of renal failure. Biopsy
findings included tubular atrophy and glomerular hyalinosis.
Although the report was entitled “Hereditary renal tubular aci-
dosis” complete RTA was present in only one patient and
impaired urinary acidification without acidosis in another three,
while six had nephrocalcinosis and 19 had hypercalciuria, and the
authors themselves made the point that the acidification defect
was probably a consequence of the hypercalciuria [20]. Thus, the
clinical features of this inherited renal tubular disorder would be
completely consistent with the diagnosis of XLHN.
In 1962, Gentil and colleagues in Paris described two boys with
hypophosphatemic rickets, hypercalciuria, urinary loss of both
albumin and LMW proteins, polyuria, and normal ability to
acidify the urine. Renal biopsies documented an “interstitial
nephropathy,” consistent with those described in documented
cases of XLHN [21]. In 1979, Salti and Hamadi reported a
Lebanese boy with hypercalciuric rickets, “tubular” proteinuria,
glycosuria, aminoaciduria, hypophosphatemia, impaired urinary
concentration, and normal urinary adicification. The authors were
struck by the similarities between their patient and those of Gentil
et al and of Dent and Friedman [22].
Carey and Hopfer described a 12-year-old Puerto Rican boy
with hypophosphatemic rickets, hypercalciuria, b2-microglobulin-
uria, aminoaciduria, and microscopic hematuria. His maternal
grandfather had nephrolithiasis and his sister had hypercalciuria.
Hypercalciuria was diet-dependent, and also improved on therapy
with thiazide [23].
Furuse et al reported two Japanese families in which an
inherited Fanconi syndrome occurred in six male individuals [24].
Fig. 1. Pedigree of extended family with X-linked recessive nephrolithiasis. Males are indicated by squares, females by circles, and affected patients
by solid symbols. Four patients not initially identified in the original report as affected are now indicated by solid symbols (subjects III-11, V-15, V-34,
and VI-2). (Adapted from Frymoyer et al [1], with permission. Copyright © 1991, Massachusetts Medical Society. All rights reserved.)
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Urinary abnormalities included low-molecular weight proteinuria
and hypercalciuria, and appeared to be progressively more severe
with advancing age. This condition resembled the syndromes of
XLHN in the occurrence of renal failure, the findings on renal
biopsy, and the excessive urinary excretion of b2-microglobulin in
all of the patients and unaffected carriers. The pedigree was
consistent with an X-linked recessive mode of inheritance [24]. To
my knowledge no molecular studies have been pursued in these
patients.
One condition that is tempting to compare with XLHN is that
described in a Bedouin tribe by Tieder et al as hereditary
hypophosphatemic rickets with hypercalciuria (HHRH) [25, 26].
Patients with HHRH had rickets, hypophosphatemia with appro-
priate elevation in serum levels of 1,25-dihydroxyvitamin D,
hypercalciuria, and relatively low PTH levels. Thus, in several
ways they resembled the Italian and French families with X-linked
rickets discussed above. Hypercalciuria appeared to reflect intes-
tinal hyperabsorption of calcium. One of these six children had
cystolithiasis, but none had proteinuria, aminoaciduria, glycos-
uria, or uricosuria, and all had normal glomerular filtration rates
[25]. It is of great interest that about 40% of members of this tribe
had (apparently asymptomatic) hypercalciuria with a similar
metabolic pattern, though milder and without rickets [26]. Inter-
pretation of the inheritance pattern was difficult in view of the
extensive intermarriage among families in this tribe, but several
instances of male-to-male inheritance of hypercalciuria argued
against X-linked inheritance [26], and the absence of proteinuria
in particular also makes it unlikely that this represents a form of
XLHN. The metabolic features of this syndrome make it tempting
to propose that it is explained by dysfunction of the Na-dependent
phosphate transporter NaPi2, and this transporter is encoded by a
gene on chromosome 5 (5q35) [27].
COMMON CLINICAL FEATURES OF THE X-LINKED
HYPERCALCIURIC NEPHROLITHIASIS SYNDROMES
If X-linked hypercalciuric nephrolithiasis is to be classified as a
form of the Fanconi syndrome it must be kept in mind that while
LMW proteinuria is a consistent finding, other defects of proximal
tubular function are variable and intermittent, that proximal renal
tubular acidosis does not occur, and that it differs from most other
forms of the Fanconi syndrome in the nature of the abnormalities
of calcium metabolism.
Proteinuria
The degree of proteinuria is relatively consistent across the
spectrum of reports of this disease. Total excretion of proteins in
most cases amounts to 0.5 to 2 grams per day in adults and up to
1 g per day in children [1, 2, 8, 10, 13, 16, 24], with 50 to 70% of
the total consisting of LMW proteins with molecular mass of less
than 40,000 daltons [13, 14, 16, 24] (and Anthony Norden,
personal communication). Albumin represents less than half of
the protein excreted by these patients, and the nephrotic syn-
drome does not occur in any of the X-linked hypercalciuric
nephrolithiasis syndromes. The defects in renal tubular function,
the degree of proteinuria, and the histopathology (described
below) together most strongly suggest that the albuminuria re-
flects glomerular damage secondary to tubulointerstitial disease.
Figure 2 illustrates the excretion of LMW proteins in the large
pedigree that formed the basis for the description of XRN.
Affected males excreted b2-microglobulin in amounts that ex-
ceeded the upper limit of normal by 100- to 300-fold, and
retinol-binding protein in amounts that exceeded the upper limit
of normal by 1000- to 3000-fold. Obligate carrier females excreted
a moderate excess of b2-microglobulin and retinol-binding pro-
tein. Excretion of a1-microglobulin followed a similar pattern [2].
This is consistent with X-linked recessive inheritance, with ran-
dom inactivation of the X chromosome yielding a variable phe-
notype in females that is almost always less severe than in affected
males. Essentially identical findings have been reported in the
British families [8] one of the Italian families [18], and the
recently-described French family [12], and a number of Japanese
reports described similar findings for b2-microglobulin, a1-micro-
globulin, and lysozyme [13, 14, 16, 24].
Although low molecular-weight proteinuria is a nonspecific
finding in many tubulointerstitial diseases, it is uncommon in
stone disease in the absence of infection or obstruction from
recurrent stones [28]. In contrast, low-molecular-weight protein-
uria is one of the earliest and certainly the most consistent
abnormality found in affected males in all families with XLHN,
and for this reason excretion of these low molecular-weight
proteins is useful as a screening test for this disease.
Urinary protein markers of tubular injury were normal in
British patients with Dent’s disease [8]. Urinary levels of n-acetyl
glucosaminidase were abnormal in a number of patients in two
Japanese reports [14, 24], but one of these was a report of LMW
proteinuria with no mention of hypercalciuria or nephrocalcinosis
[14], and neither has been confirmed by anlysis of CLCN5 for
mutations.
Hypercalciuria
Hypercalciuria in adults with XLHN tends to be modest,
usually in the range of 4 to 6 mg/kg body wt even on a high calcium
intake and even when renal function is still well-preserved. In
some children, however, we have seen calcium excretion rates as
high as 10 mg/kg body wt. In cases in which thiazides have been
given, hypercalciuria often has improved, though usually not to
normal. These anecdotal observations on thiazides need to be
pursued in properly controlled studies.
In studies involving dietary deprivation and loading, we have
found fasting hypercalciuria in about half of patients with XRN,
but all patients have an exaggerated calciuretic response to oral
calcium loading [2]. In two Japanese children with LMW protein-
uria and nephrocalcinosis, Igarashi observed fasting hypercalci-
uria with a post-absorptive rise in urinary calcium. They observed
a mildly increased urinary cAMP excretion on fasting that sup-
pressed with oral calcium loading, but PTH levels were in the
low-normal range in both patients [16], as was found in 15 of the
16 published cases on three continents (Fig. 3). Serum calcium
levels in XRN, Dent’s disease, and the Japanese children, have all
been normal, with no tendency to hypocalcemia [1, 2, 8, 16].
Figure 3 depicts the serum levels for PTH and 1,25 dihydroxyvi-
tamin D only in those patients with normal rates of creatinine
clearance, in each of the four published XLHN syndromes, and in
additional patients whom we are currently studying. Patients from
North America, England, Italy, and Japan, with only one excep-
tion, all have PTH levels below the mean of the normal range and
often frankly low, and all have 1,25 dihydroxyvitamin D levels that
are above the normal mean or frankly elevated. Serum levels of
phosphorus were normal in most of these patients, though often
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near the low end of the normal range. In these respects, calcium
metabolism in XRN is similar to one pattern commonly seen in
patients with idiopathic hypercalciuria. In addition, the combina-
tion of hypercalciuria with high levels of 1,25 dihydroxyvitamin D
contrasts with other renal diseases in which hypocalciuria and
normal to low levels of 1,25 dihydroxyvitamin D is a more
common pattern.
If the molecular defect in this disease led directly to a renal
tubular leak of calcium, one might expect PTH levels to be high,
or at least not low. This, and the exaggerated calciuretic response
to dietary calcium loading, make it reasonable to speculate that
the hypercalciuria may be the consequence of abnormal regula-
tion of 1-hydroxylation of vitamin D, possibly as a part of more
generalized dysfunction of the proximal tubular cell.
Factors contributing to stone risk
The most significant factor contributing to calcinosis and stone
formation appears to be hypercalciuria. Urinary supersaturation
for calcium oxalate is high, particularly when corrected for the
patients’ large urine volumes [29]. Urinary excretion of oxalate
was slightly elevated in one of six male patients with Dent’s
disease [8] and was normal in all of the published cases of XRN
[1, 2] but was slightly high in one patient with XRN we have
subsequently seen (unpublished observation). Urinary excretion
of citrate was normal in all patients with XRN [1, 2] and in all 5
patients with Dent’s disease in whom it was measured, except for
one patient who had renal insufficiency [8]. Wrong and colleagues
pointed out that this is unlike the findings in typical Fanconi’s
syndrome, in which citrate excretion is often high [8].
Other defects of proximal tubular function
While LMW proteinuria is universal in X-linked hypercalciuric
nephrolithiasis, other defects of proximal tubular function occur
less consistently. Aminoaciduria occurred in 14 of 15 of Wrong’s
patients with Dent’s disease, and in five included most promi-
nently glycine. However, we observed a nonselective pattern of
aminoaciduria in patients with advanced renal failure in XRN [1],
while a specific pattern of dibasic aminoaciduria happened to
occur in a number of normal family members and in two carrier
females but in none of the other affected males, and could be
demonstrated by linkage analysis to segregate independently of
X-linked nephrolithiasis [2]. Aminoaciduria was reported in 1 of 5
patients in Suzuki’s report of LMW proteinuria in Japan [13], 2 of
6 males in Igarashi’s report [16], and 5 of 37 in Murakami and
Kawakami’s report [14]. Dibasic aminoaciduria occurred in 6 of 6
male members of Furuse’s families with “familial progressive
renal tubulopathy” [24].
Renal glycosuria occurred in fewer than half of patients in each
of a number of reports [2, 8, 14, 16, 24] and was often intermittent
[8]. Hypokalemia was certainly uncommon, but when it occurred
could require substantial quantities of potassium replacement [1,
2, 8, 24]. Hypophosphatemia with a reduced threshold for phos-
phate reabsorption also occurred in a minority of patients [1, 2, 8,
24]. Hyperuricosuria was reported in 3 patients with XRN [1] and
in 2 of 15 patients with Dent’s disease [8], but all had normal
serum levels of uric acid so this should not be interpreted to
reflect an alteration in tubular reabsorption [1, 2, 8]. We have seen
one young boy with mild hypouricemia (1.4 mg/dl) and hyperuri-
cosuria (unpublished observation).
Defects in renal sodium reabsorption have not been demon-
strated and patients have not been studied after severe restriction
of dietary sodium intake. The absence of hypertension in all
reported patients (except one with advanced renal failure [8])
argues against an inappropriate retention of sodium. Our patients
were able to tolerate a moderate (2 g/day) restriction of sodium
intake without alteration in blood pressure [2]. Wrong reported
one patient with an exaggerated natriuretic response to a large
dose of thiazide diuretic [8].
Defective urinary concentration and acidification
Moderate polyuria and relative resistance to vasopressin oc-
curred in many patients including young children [2, 8]. Osmolar
clearance was normal indicating that the polyuria did not result
from a solute diuresis from proximal tubular failure, nor did it
correlate with the presence or absence of hypokalemia [2]. In all
cases the impaired concentrating ability was consistent with the
degree of renal insufficiency or nephrocalcinosis [2, 8]. Metabolic
acidosis was absent in all but those patients with advanced renal
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Fig. 2. Urinary excretion of the low-molecular-
weight proteins b2-microglobulin and retinol-
binding protein in affected males, obligate
carrier females, and normal members of the
large family reported with XRN. Horizontal
lines indicate the established upper limit of the
normal range. (Adapted from Reinhart et al
[2], with permission.)
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insufficiency. Urinary acidification defects detectable with acid-
loading were identified in a number of patients and again could be
explained in each case by renal insufficiency or nephrocalcinosis
[2, 8].
Renal failure
The occurrence of renal failure in this disease is variable. Some
patients have significant depression of GFR by late childhood and
may reach end-stage renal disease in their 30s, while others may
have only modest impairment of renal function into old age. The
cause of renal failure is not clear. Nephrocalcinosis is a common
finding in virtually all patients from teenage years onwards, and is
occasionally detectable in young children. Histologically and
radiographically, the nephrocalcinosis is medullary. However, the
severity of nephrocalcinosis does not correlate consistently with
the presence or degree of renal insufficiency.
Findings on renal histopathology are nonspecific. Most promi-
nent is tubular atrophy and interstitial fibrosis, with glomeruli
exhibiting varying degrees of sclerosis, and some glomeruli hyper-
trophic. The biopsy appearance is that of a focal tubulopathy with
atrophy and scarring but little if any inflammation, and secondary
glomerular damage. Ultrastructural examination by electron mi-
croscopy reveals normal basement membranes, and immunofluo-
rescence studies have been negative [1, 8, 16].
I am aware of at least nine cases of XRN and Dent’s disease,
both published [1, 8] and unpublished, in which renal transplan-
tation has been performed, and which have been followed for as
long as 12 years. In no case has nephrolithiasis or nephrocalcinosis
developed in the transplant. The persistence of LMW proteinuria
or aminoaciduria [8] after transplantation is of uncertain signifi-
cance, as they could reflect nonspecific allograft injury or some
residual function from the native kidneys.
Rickets/osteomalacia
Rickets was a prominent feature in about a third of patients
reported with Dent’s disease, and in all nine affected males in the
Italian and French families with X-linked recessive hypophos-
phatemic rickets. The cause of the rickets was and remains
unclear. No reported patient with any of these syndromes was
hypocalcemic, and bone disease could not be explained by acido-
sis. Hypophosphatemia was present in six of fifteen affected males
with Dent’s disease, but the degree of hypophosphatemia did not
correlate with the presence of rickets, and in most cases did not
distinguish patients with rickets from those with either Dent’s
disease or XRN who did not have rickets. For example, of the
three patients in the report by Wrong, Norden and Feest with the
most severe hypophosphatemia, only one had rickets or osteoma-
lacia [8]. Two of the four rachitic French patients were normo-
phosphatemic [12].
Serum levels of alkaline phosphatase were elevated in patients
with clinical bone disease [8] but were normal in patients without
bone disease [1, 2, 8]. In addition to normal levels of alkaline
phosphatase, patients with XRN had normal bone mineral den-
sities measured by dual-energy x-ray absorptiometry [2]. Healing
of the bone disease occurred with large doses of vitamin D in all
of the rachitic children with Dent’s disease [8].
POSITIONAL CLONING OF THE GENE CLCN5
The clinical findings in patients with X-linked hypercalciuric
nephrolithiasis did not provide clear clues to the nature of the
primary pathophysiologic defect. Early attempts to address this
included measurements in erythrocytes of the activities of the
Na-K-Cl cotransporter, K-Cl cotransporter, Na/K-transporting-
ATPase, and carbonic anhydrases B and C, all of which were were
normal in patients with XRN [1]. The disease was difficult to
explain a priori on the basis of a defect in any single transport
protein or pathway.
However, the availability of an extended family with XRN with
a pedigree providing compelling evidence of X-linkage made
possible a genetic approach to localize the gene and identify it by
positional cloning. Working with Dr. Raj Thakker of the Ham-
mersmith Hospital in London, we focused our localization efforts
on the X chromosome, using restriction fragment length polymor-
phisms (RFLPs) and microsatellite polymorphisms on DNA
extracted from peripheral blood leukocytes in 102 members of the
extended pedigree. We were extremely fortunate in that the first
marker we tried that was informative in this family exhibited
linkage with the disease. This marker was a highly polymorphic
RFLP at locus DXS255 identified by the probe M27b after
digestion with the restriction enzyme EcoRI. Figure 4 illustrates in
one small branch of this pedigree the results with this RFLP. In
this branch and across the entire family, affected males all
displayed the 7.5 kb allele, carrier females were heterozygous for
this allele, and unaffected males displayed other alleles. With only
one unaffected recombinant (3.6% recombination), this locus was
highly linked with the disease, with a LOD score of 5.91,
indicating odds favoring linkage of nearly one million to one for
this locus at Xp11.22, in the pericentromeric region of the short
arm of the X chromosome [30]. This region harbors genes
PTH
1,25(OH)2D
Fig. 3. Serum levels of intact PTH and 1,25-
dihydroxyvitamin D in patients with XLHN
syndromes in whom creatinine clearance rates
were documented to be normal. Except for two
of the Japanese cases, all patients shown have
been confirmed to have CLCN5 mutations. The
boxes indicate the limits and midpoints of the
normal ranges for PTH and 1,25
dihydroxyvitamin D, respectively. Symbols
indicate sources of data: North American
patients with XRN (original report, F [2]; other
North American cases, f [3–5, and unpublished
observations]); British patients with Dent’s
disease (M, [8]); Italian cases with rickets (,
[10]); and Japanese cases with LMW
proteinuria and nephrocalcinosis (E, [14]).
Scheinman: X-linked hypercalciuric nephrolithiasis8
responsible for a number of eye diseases, but detailed ophthal-
mologic examination of patients with XRN failed to reveal any
structural or functional abnormalities [2].
This localization, as well as the clinical and histologic features,
allowed a definitive answer to the question of the relationship
between XRN and two other important diseases. One is the
oculocerebrorenal syndrome of Lowe, the only other X-linked
Fanconi syndrome. Patients with Lowe’s syndrome occasionally
develop renal failure. However, the neurologic and eye findings of
Lowe’s syndrome are absent in XLHN. The other disease, Al-
port’s syndrome, is the most common X-linked cause of renal
failure, but Alport’s syndrome is not associated with nephrolithi-
asis, no patient with XRN had a hearing deficit, and most
importantly, renal biopsies in patients with XRN or other XLHN
syndromes all failed to demonstrate the abnormalities of the
glomerular basement membrane that are characteristic of Al-
port’s syndrome. In addition to these important phenotypic
differences, the chromosomal location of the gene for XRN, in
the pericentromeric region of the short arm of the X-chromosome
(Xp11.22), clearly distinguished it from both of these other
conditions which have been mapped to the long arm (Lowe’s at
Xq25 to 26 [31] and Alport’s at Xq22 [32]). Figure 5 illustrates the
relative positions on the X chromosome of the diseases affecting
renal function that have been mapped on that chromosome.
Knowledge of the localization of XRN also made it possible to
address the issue of the relationship between XRN and Dent’s
disease. In the British patients with Dent’s disease, the apparent
occurrence of clinical disease in one female, and the low molec-
ular-weight proteinuria in all female carriers, originally led Wrong
and colleagues to propose that this syndrome was autosomal [7].
However, using markers in the region to which XRN had been
localized, the Thakker group discovered in the largest of the
British families with Dent’s disease not just linkage to the same
locus, but exciting evidence for a deletion of that locus [33]. In
collaboration with Dr. Ian Craig’s group at Oxford University they
determined the size of this deletion in this family to be about 515
kb [34]. Yeast artificial chromosomes that spanned the deletion
were used to screen a human renal cDNA library, and a candidate
gene was identified [34].
This gene had a novel sequence, and was homologous to the
family of voltage-gated chloride channels. Current nomenclature
is unfortunately confusing, with the gene designated CLCN5, and
the channel protein it encodes designated CLC-5. The gene had
13 exons, and the transcript was 9.5 kb in size, with an open
reading frame of 2238 bases encoding a product of 746 amino
acids, with 12 predicted transmembrane domains [35].
The first of the genes in this family had been identified by
Thomas Jentsch by expression cloning from the marine ray
Torpedo marmorata. The mammalian members of this family of
channels are represented in Figure 6. These include CLC-1, the
major chloride channel in human muscle, which is the gene
mutated in both the dominant and recessive forms of congenital
myotonia, the only other disease currently associated with muta-
tions in this family of genes [36]. CLC-Ka and CLC-Kb are
expressed exclusively in kidney, and their axial distribution along
the nephron has been studied [37]; one of them appears to be the
basolateral chloride channel in medullary thick ascending limb
[38]. In the rat, expression of the homologues of CLC-Ka and
CLC-Kb can be induced by dehydration [39, 40]. These two
channels, however, share only about 30% amino acid identity with
CLC-5. Sequences for CLC-3 and CLC-4, both of which are
expressed broadly including in kidney, are about 77 to 78%
identical to CLC-5 [35].
On Northern analysis CLC-5 appears to be expressed in
humans primarily in the kidney [34]. In the rat, on the other hand,
CLC-5 expression can be demonstrated in brain, liver, and lung,
though as in human the predominant expression is in kidney [41].
Bone cells have not yet been examined for expression of CLC-5.
In the rat, CLC-5 is expressed throughout the nephron with the
exception of the glomerulus [41], but particularly since the
distribution of CLC-5 expression in extrarenal tissues differs
significantly between rat and humans [41, 42], we must be cautious
about extrapolating observations on intrarenal localization from
rat kidney to human.
kb
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Fig. 4. Restriction fragment length
polymorphism revealed by probe M27b
identifying locus DXS255 in one branch of the
extended family with XRN reported by
Frymoyer et al [1]. Five micrograms of
leukocyte DNA was digested to completion
with a fourfold excess of enzyme (EcoRI),
electrophoresed and transferred to a nylon
membrane (Hybond N) by Southern blotting.
The DNA probe was labeled using a-32P dCTP,
hybridized to the Southern blot and detected by
autoradiography. Seven alleles were identified
in the entire family for this highly polymorphic
marker, of which three are seen on this Figure.
The affected males (f) had the 7.5 kb allele,
and none of the unaffected males (M) had this
allele. Two obligate heterozygote females are
illustrated, indicated by a dot in the circle; both
are heterozygous for this marker, and both have
the 7.5 kb allele. Altogether in the family there
were 24 meioses informative for this marker, of
which 23 were non-recombinant. (Data from
Scheinman et al [28].)
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CLCN5 MUTATIONS IN X-LINKED HYPERCALCIURIC
NEPHROLITHIASIS
Upon identification of a candidate gene, mutations were sought
and identified in patients with XRN, Dent’s disease, and X-linked
recessive hypophosphatemic rickets, demonstrating that these
three syndromes with overlapping phenotypes all shared a com-
mon molecular basis [43]. Soon thereafter, mutations were found
in Japanese families with LMW proteinuria and nephrocalcinosis.
Thus, the question posed by Igarashi and colleagues in the title to
their report, “Is the disease identical to Dent’s disease in the
United Kingdom?” [16], has been answered in the affirmative.
Mutations have been found in four families with XRN [19, 43], ten
families with Dent’s disease including one of Dent’s original
patients [19, 43], and the Italian and French families with X-
linked recessive hypophosphatemic rickets [12, 43] as well as in
the Italian family without rickets [19]. Five mutations have been
documented in six Japanese families [17, 44].
To date 19 different mutations have been reported in 22
unrelated families (Table 2 and Fig. 7). These include 8 missense
mutations leading to substitutions of single amino acids; 5 non-
sense mutations leading to stop codons that yield a truncated
protein; one in-frame insertion of an triplet encoding histidine; 2
donor splice-site mutations and one in-frame deletion that lead to
loss of one or more transmembrane domains; one insertion of a
single base resulting in a frameshift that truncates the protein; and
the deletion of the entire gene found in the family from Kent.
The identification of point mutations in CLCN5 not only
— XLHN
— Fabry's disease
— Alport syndrome
— Lowe syndrome
— Nephrogenic diabetes
insipidus
— Hypophosphatemic
rickets
Xp22.1
Xp11.22
Xq22
Xq22
Xq25-q26
Xq28
Fig. 5. Genes responsible for X-linked disorders affecting the kidney are
indicated schematically at their relative positions on this cartoon of the X
chromosome. Localization data taken from references [11, 31, 32, 77, 78].
CLC-1
CLC-2
CLC-Ka
CLC-Kb
CLC-3
CLC-4
CLC-5
CLC-6
CLC-7
Fig. 6. The nine known members of the CLC family of voltage-gated
chloride channels in mammals. The dendrogram represents the relative
similarities among these channel proteins based on amino acid sequence
(From Brandt and Jentsch [79], used with permission).
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Fig. 7. Schematic representation of the amino acid sequence of CLC-5 with predicted topology, revised from Lloyd et al [43] to indicate the 18
mutations published to date. Mutations are identified by numbers as listed on Table 2. Solid circles represent missense (1 to 8) and nonsense (9 to 13)
mutations; triangles indicate insertion of a triplet codon [14] and a single base causing a frameshift [18]; and pairs of curved brackets represent the
boundaries of the sequence of amino acids deleted as a result of two donor splice-site mutations (15 and 16) and an intragenic deletion [17]. (A
chromosomal microdeletion encompassing the entire gene represents the 19th known mutation.) (Figure is used with permission of Nature.)
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Table 2. Published mutations in CLCN5 in patients with X-linked hypercalciuric nephrolithiasis
Codon Base change Amino acid change Predicted effect Expression Source Phenotypea Ref
Missense
1 57 GGC3GTC Gly3Val D1 helix Reduced U.S.A. 1,2,3,4 [19]
2 200 CTG3CGG Leu3Arg D3 charge distribution Abolished U.K. 1,2,3,4,5 [43]
3 244 TCG3TTG Ser3Leu D5 helix Reduced Italy 2,3,4,5 [43]
244 TCG3TTG Ser3Leu D5 helix France 1,2,5 [12]
4 280 CGT3CCT Arg3Pro at border of D6 Reduced Japan 1,2,3 [17]
5 506 GGG3GAG Gly3Glu D11 charge distrib Abolished U.S.A. 1,2,3,4 [43]
6 512 GGT3CGT Gly3Arg D11 charge distrib Abolished U.S.A. 1,2,3,4 [19]
7 520 TCT3CCT Ser3Pro D11 helix Reduced U.K. 1,2,3,4,5 [43]
8 527 GAA3GAT Glu3Asp ?[highly conserved] Abolished India 1,2,3,4,5 [19]b
Nonsense
9 279 TGG3TGA Trp3Stop Lose 467 aa Abolished U.K. 1,2,3,4 [43]
279 TGG3TGA Trp3Stop Lose 467 aa Japan 1,2,3 [17]
10 343 TGG3TAG Trp3Stop Lose 404 aa Japan 1,2,3 [17]
11 347 CGA3TGA Arg3Stop Lose 399 aa Japan 1 [44]
12 648 CGA3TGA Arg3Stop Lose 98 aa Abolished U.K. 1,2,3,4,5 [43]
648 CGA3TGA Arg3Stop Lose 98 aa Italy 1,2,3,4 [19]
13 704 CGA3TGA Arg3Stop Lose 42 aa Abolished Canada 1,3,4 [43]
Insertion
14 30 ACC in-frame
insertion
30:H insertion ?charge distrib Reduced U.K. 1,2 [19]b
Splice-site
15 132-172 del gt3gg Lose 41 amino acids Lose D2 Abolished U.K. 1,2,3,4,5 [43]
16 132-172 del gt3at Lose 41 amino acids Lose D2 Abolished U.K. 1,2,3,4 [43]
Deletions
17 132-241 (2 kb) Lose 110 amino acids Lose D2-D4 Abolished U.K. 1,2,3,4,5 [43]
(ns.) entire gene (515 kb) Protein absent No protein U.K. 1,2,3,4,5 [33]
18 695 DC D695fs3699 Stop Lose 47 aa Japan 1,2,3 [17]
a Phenotypic features: 1 5 LMW proteinuria; 2 5 hypercalciuria; 3 5 nephrocalcinosis/stones; 4 5 renal insufficiency; 5 5 rickets
b Clinical data from Prof. Oliver Wrong, personal communication
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established that this is the gene responsible for the disease
phenotype, but also provides information regarding on structure/
function relationships in the CLC-5 channel. Nearly all of these
mutations have been studied by expression in Xenopus oocytes in
the laboratory of Dr. Thomas Jentsch. Each mutation when
expressed yielded a channel protein that either abolished or
markedly reduced the chloride currents measured at positive
voltages. Thus, the disease X-linked hypercalciuric nephrolithiasis
results from inactivation of this chloride channel. This is consis-
tent with the recessive pattern of inheritance.
Missense mutations, designated 1 to 8 on Figure 7, result in
substitution of a single amino acid in a channel that is otherwise
unaltered. All of these 8 occur in or near transmembrane do-
mains, and all affect sequences that are highly conserved among
members of the CLC channel family. Four of these (Leu200Arg,
Gly506Glu, Gly512Arg, and Glu527Asp) yielded chloride cur-
rents in Xenopus that were indistinguishible from water-injected
controls, and thus appear to abolish channel function. Three
others (Ser244Leu, Ser520Pro, and R280P) led to chloride cur-
rents that were markedly reduced. A fourth missense mutation
(Gly57Val) and an in-frame insertion of a triplet encoding
histidine (designated #14 on Fig. 7) both led to currents that were
moderately (50 to 70%) reduced, compared with currents pro-
duced with the wild-type sequence. These latter two mutations
occur near the amino-terminal end of the protein, in sequences
that are less well-conserved among members of the CLC chloride-
channel family [19].
One of the missense mutations (Glu527Asp) and the triplet
insertion (30:His) are de novo mutations, as evidenced by the
absence of the mutation in the parents in each case. The
Glu527Asp mutation was passed along by the affected male
patient to each of his two daughters.
The five nonsense mutations leading to truncation of the
protein occur throughout the sequence. All four of these that have
been expressed have resulted in abolition of chloride currents,
including the least disruptive one, R704X, which leads to loss of
42 amino acids from the cytoplasmic C-terminal end of the
protein. A frameshift at codon 695 has not been expressed, but as
this mutation results in a stop codon at 699 it should similarly
abolish function. In addition, the two donor-splice-site mutations
(mutations 15 and 16 on Fig. 7) lead to loss of 41 amino acids
encompassing the second transmembrane domain D2. Expression
of this deletion in Xenopus yielded chloride currents indistinguish-
able from water-injected controls, indicating abolition of channel
function. The functional importance of D2 had been questioned
based on a report that expression of a variant of rCLC-K2 deleted
for D2 still led to a functional channel [45]. However, this
observation has not been widely accepted [39, 46, 47], and
Jentsch’s expression of the D2 deletion in CLC-5 supports a
significant role for this segment of the protein, most likely as a
transmembrane domain [43].
Two of the nonsense mutations have each been found in
separately identified and unrelated families. The G-to-A transver-
sion at codon 279 that results in a stop codon has been found in
a British family and in a Japanese family [17, 43], and the C-to-T
transversion yielding a premature stop signal at codon 648 oc-
curred in an Italian family and in a British family [19, 43]. In each
case haplotype analysis using microsatellite polymorphisms con-
firmed that the families were unrelated.
There appears to be no correlation between the nature of
mutation and the phenotype. Individuals with missense mutations
may be as severely affected as others with stop codons or deletion
of the entire gene. The mutation with the mildest effect on
chloride currents when expressed in Xenopus (50% reduction) is
the arginine-for-glycine substitution at the start of the first
transmembrane domain (mutation #1), and yet several members
of this family (from Florida) have had recurrent nephrolithiasis
and progressive renal failure requiring dialysis and transplanta-
tion, though not rickets [5]. In addition, within families, individ-
uals sharing the same mutation can be mildly or severely affected.
In the American family in which we first described XRN, the
mutation (#5) resulting in substitution of glutamate for glycine in
the 11th transmembrane domain is associated with severe renal
failure before age 40 in some patients, recurrent nephrolithiasis
with preserved renal function in other patients [1, 2], and a more
benign course in at least two patients (unpublished observations).
Some patients in the British family with complete deletion of the
entire gene are less severely affected than some individuals in
other families with missense mutations.
Symptomatic rickets, presenting with deforming bone disease in
childhood, occurred in some of the patients with Dent’s disease
originally reported by Wrong et al [8], who turn out to have a
variety of mutations including missense (mutations #2 and #7),
nonsense (mutation #12), and a splice-site mutation leading to
loss of a transmembrane domain (#15). In each of these four
families, only one member has rickets, and in each of these
families, other affected individuals share the same mutation but
manifest disease with differing severities and without rickets. In
only two families has rickets appeared to be the predominant
clinical feature; these are the Italian and French families reported
as X-linked recessive hypophosphatemic rickets [10, 12]. Affected
members of both of these families have a missense mutation
leading to substitution of leucine for serine at the fifth transmem-
brane domain, which yields a markedly reduced though detectable
chloride current when expressed in Xenopus [43], and is not
clearly different from a number of the other mutations.
Such phenotypic variation is not uncommon in genetic diseases.
In XLHN, it is not yet known to what extent environmental factors
or other modifying genes may alter severity of the disease
phenotype, although it is clear that the nature of the CLCN5
mutation alone is not sufficient to determine the expression of the
clinical disease.
STRUCTURE OF CLC CHLORIDE CHANNELS AND
FUNCTION OF CLC-5
Hydropathy analysis of the amino acid sequences predicts a
similar basic transmembrane structure for all members of the
CLC family of voltage-gated chloride channels [35]. A model of a
possible structure is illustrated on Figure 7, which displays 12
transmembrane domains, as proposed by Jentsch et al [46]. A
weakly hydrophobic sequence once considered a transmembrane
domain (D4) is now felt to be extracellular. The sequence linking
the 8th and 9th transmembrane domains had been thought to be
intracellular, but contains a potential glycosylation site that has
now been confirmed in several other members of this channel
family, using in vitro translation and site-directed mutagenesis, in
fact to be glycosylated, establishing its extracellular position [46].
The segment from the 9th through the 12th transmembrane
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domains as pictured represents a broad hydrophobic region,
essentially the same in all members of the CLC family, in which
the number of transmembrane crosses is proposed to be uneven
[35, 46].
Chloride channels of this family are thought to function as
multimeric complexes, which would explain the dominant nega-
tive effect of mutations in CLC-1 in the dominant form of human
congenital myotonia (Thomsen’s disease) [46]. Our current un-
derstanding of the electrophysiologic properties of these channels
is dependent largely upon study of them as expressed in Xenopus
oocytes, and some members of this gene family do not yield
chloride currents when expressed, or have led to controversial
results [36, 46], perhaps because physiologic activity requires the
presence of other subunits. Preliminary studies so far have not
revealed functional interactions when CLC-5 was coexpressed
with other members of this family [48]. If CLC-5 does function
physiologically as a heteromultimer, the electrophysiologic fea-
tures of the functional channel in humans may well differ from
that observed when it is expressed alone in Xenopus. Both the
human [17, 19, 43] and rat [41] CLC-5 sequences have been
expressed by Jentsch, and resemble the other CLC channels that
have been expressed successfully (CLC-0, CLC-1 and CLC-2) in
having a high selectivity for chloride. However, CLC-5 differs
from those members of the CLC family in that it yields currents
that are strongly outwardly rectifying and are activated at inside-
positive plasma membrane voltages exceeding 1 10 to 20 mV [36,
41–43].
CLC-5 bears little if any relation to the cystic fibrosis trans-
membrane conductance regulator (CFTR), which also conducts
chloride currents and appears to be expressed in all segments of
human renal epithelium [36]. Microscopic nephrocalcinosis has
been reported in cystic fibrosis, occurring even at infancy, and
with hypercalciuria in a third of such patients. However, clinically
significant renal dysfunction is absent and histology is otherwise
unremarkable even at sites of calcinosis [49]. While the sequence
for CLC-5 predicts a potential cytoplasmic cAMP-dependent
phosphorylation site, the rat CLC-5 expressed in Xenopus failed to
respond to raising intracellular cAMP concentrations [41].
PHYSIOLOGY OF CLC-5 AND POSSIBLE
PATHOPHYSIOLOGY OF X-LINKED HYPERCALCIURIC
NEPHROLITHIASIS
We do not yet know enough about the physiology of the CLC-5
chloride channel to say how these mutations result in a syndrome
of proximal tubulopathy, hypercalciuria, and renal failure. Since
the earliest and most consistent clinical features are low-molecu-
lar-weight proteinuria and hypercalciuria, it will be important to
discover the role this chloride channel plays in proximal tubular
function and calcium metabolism. When the expression of CLC-5
along the human nephron becomes known, we might reasonably
expect that it will be found at least in proximal tubule. The
vasopressin-resistant polyuria might suggest a role for CLC-5 in
distal nephron as well, since polyuria occurs in patients whose
hypercalciuria appears too mild to account for it.
Acidification of endocytic vesicles in proximal tubule has been
shown to involve a protein kinase A-regulated chloride conduc-
tance [50]. A number of authors have pointed out the potential
importance of chloride channels in the lysozomal vacuoles that
degrade proteins taken up from the proximal tubular lumen. Such
channels would provide an inward chloride flux to dissipate the
positive charge resulting from active proton secretion into these
vacuoles. Thus, it has been speculated that inactivation of CLC-5
might lead to impaired vacuolar acidification and thus impaired
reabsorption of LMW proteins [35, 41, 43, 51]. This hypothesis
has been challenged, however, based on the voltage-gating char-
acteristics of CLC-5 [52]. Chloride channels have been studied in
endosomal vesicles from proximal tubule, and the conductance,
ion selectivity, and inhibitor sensitivities [53] all differ from those
reported for CLC-5 [41].
Several authors have speculated on the possible role of CLC-5
in calcium reabsorption [47, 51, 52]. It is difficult to propose a
specific effect of CLC-5 on calcium reabsorption in the proximal
tubule, where transepithelial movement of calcium is mainly
passive and paracellular. Chloride channels may play a role in
calcium reabsorption in the medullary thick ascending limb
(MTAL), where a basolateral chloride channel participates in
transepithelial chloride transport. However, the ion selectivity,
inhibition by NPPB, and activation by cAMP reported for the
basolateral chloride current in MTAL all differ from the proper-
ties of CLC-5, at least in the rat [41]. Furthermore, recent studies
in the rabbit indicate that CLC-Ka is the basolateral chloride
channel in the thick limb [38]. In the distal convoluted tubule,
both thiazides and PTH have been reported to bring about their
stimulatory effect on calcium transport through activation of
chloride channels with consequent cell hyperpolarization [54, 55].
Thus, inactivation of such chloride channels could lead to hyper-
calciuria. However, renal hypercalciuria might be expected to lead
to a secondary increase in PTH levels, which was clearly absent in
virtually all cases in which PTH levels were measured (Fig. 3).
The intestinal hyperabsorption of calcium in these patients
points to the potential physiologic importance of the high 1,25-
dihydroxyvitamin D levels. This, in the setting of LMW protein-
uria, may be most consistent with dysfunction of the proximal
tubular cell with resulting inappropriate activation of 1-hydroxy-
lation of 25-hydroxyvitamin D. Such activation could be a conse-
quence of renal phosphate loss (an inconsistent finding) or a
primary abnormality in the regulation of 1-hydroxylation of
25-hydroxyvitamin D; either would place the blame on the
proximal tubule. Confirmation of this speculation will require
knowledge of the localization of the CLC-5 message within the
nephron and the CLC-5 protein within the tubular epithelial cell,
and of the role of CLC-5 in renal epithelial cell function.
The cause of renal failure is also not clear, but it may not be the
result of hypercalciuria alone. Patients with XLHN are no more
hypercalciuric than many patients with idiopathic hypercalciuria
in whom renal failure does not occur in the absence of obstruction
and infection from recurrent stones, although some young chil-
dren have been very hypercalciuric. Histopathology indicates
tubulointerstitial disease, but the extent to which hypercalciuria is
the cause, a contributing factor, or merely an epiphenomenon, is
not at all known.
GENETICS OF IDIOPATHIC HYPERCALCIURIA
X-linked hypercalciuric nephrolithiasis is uncommon, and its
clinical features, particularly low-molecular-weight proteinuria,
renal failure, and rickets, clearly distinguish it from the common
forms of hypercalciuric stone disease. Idiopathic hypercalciuria
(IH), in contrast, is common, and although it is widely thought to
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have an important genetic component, the genetics of IH are
poorly understood. IH is present in 40% of patients with calcium
nephrolithiasis [56]. A family history of kidney stones can be
obtained in as many as 45% of patients with IH [57, 58]. Reports
of such families have been interpreted to indicate autosomal
inheritance of hypercalciuria [59–61]. However, there are several
reasons why it may not be correct to assume that IH is inherited
as a simple mendelian trait. One is that the distribution of calcium
excretion in the population is not bimodal, but a continuum [62],
and definitions of hypercalciuria depend upon statistical criteria
for the upper limit of the normal range that are by nature
arbitrary. Another is that there are a number of patterns of
hypercalciuria, and each may potentially represent a different
metabolic abnormality that is inherited separately or in combina-
tion in individual patients.
Idiopathic hypercalciuria, defined as hypercalciuria without
identifiable systemic cause, can be divided into as many as five
categories, including three separate patterns of absorptive hyper-
calciuria [63]. There is evidence indicating that these may repre-
sent separate pathophysiological mechanisms in which inheritance
patterns may differ [59, 64]. In addition, familial hypercalciuria
can occur in the setting of other tubular dysfunction, including
hypophosphatemia [25, 26] or hyperuricosuria [65]. Nephrocalci-
nosis in very low-birth-weight infants is strongly associated with a
history of nephrolithiasis in first- or second-degree relatives of the
parents [66].
The variety of forms of IH, and the continuous distribution of
calcium excretion in the normal population, suggest that multiple
factors, possibly multiple genes, contribute to produce the phe-
notype of high calcium excretion [57, 67]. Other common condi-
tions, including hypertension and diabetes, also appear to result
from polygenic inheritance, in contrast to the less common and
often more distinctive diseases that reflect monogenic mendelian
inheritance. This raises the question of whether CLCN5 may be
one gene among others contributing to hypercalciuria in some
patients with IH.
A large group of patients with idiopathic hypercalciuria have
exaggerated intestinal absorption of calcium, elevated serum
levels of 1,25-dihydroxyvitamin D, suppressed PTH levels, and
serum phosphorus levels that run at the lower end of the normal
range [63]. Thus, it is reasonable to speculate that some patients
with IH may have mutations in CLCN5 that may lead to less
dramatic loss of chloride-channel function than in XLHN, leading
to hypercalciuria but perhaps not the fully expressed syndrome.
To address this, we have been studying a large group of patients
with IH for clinical or molecular evidence of XLHN. Using the
most sensitive phenotypic marker of XLHN, that is, LMW
proteinuria, we have screened nearly 100 patients, and so far have
found substantial degrees of LMW proteinuria in none of them
[68]. We have also sequenced the CLCN5 gene in 8 patients with
IH, and all were normal [69]. This work continues, but at present
it appears that XLHN does not represent a large proportion of
patients with IH.
TREATMENT OPTIONS IN X-LINKED HYPERCALCIURIC
NEPHROLITHIASIS
At this stage in our understanding of XLHN, a proposed
therapeutic approach cannot be informed either by data from
clinical trials, of which there have been none, or by an under-
standing of the pathophysiology, which we currently lack despite
identification of the disease gene.
Although it is not clear how large a role is played by hypercal-
ciuria in contributing to progressive renal insufficiency in XLHN,
it does appear to be the major factor responsible for the nephro-
lithiasis. It is therefore reasonable to attempt to reduce calcium
excretion by following prudent principles that guide most therapy
in idiopathic hypercalciuria. First of all, I believe that restriction
of dietary calcium intake has no place in the therapy of this
disease. Many patients with XLHN have hypercalciuria on fasting
[16] or following calcium restriction [2], so that dietary restriction
may exacerbate the risk of bone disease. Dietary calcium restric-
tion is no longer recommended in idiopathic hypercalciuria, in
which patients have a tendency to lower bone density [70], and
particularly in view of the data in men [71] and women [72] that
lower dietary calcium intakes are associated with a higher risk of
nephrolithiasis.
Thiazide diuretics will stimulate distal tubular calcium reab-
sorption and thereby promote a positive balance of calcium, with
beneficial effects on bone mineralization [73]. A few patients with
XLHN have significant potassium wasting, and one patient devel-
oped acute volume-depletion and hypokalemia when given a large
dose of hydrochlorothiazide [8], so patients should be observed
closely at least initially when starting therapy with this class of
diuretic. I am aware of a number of patients, particularly children
with XRN, in whom therapy with a thiazide has been well-
tolerated and has reduced urinary calcium excretion, though not
always to normal. Understandable reluctance to use diuretics in
children is based on concerns over long-term side effects, and it is
sensible to identify the minimal dose that achieves the desired
effect on calcium excretion. Amiloride should also stimulate
calcium reabsorption [74], and because of its effect to inhibit
potassium secretion may be useful in XLHN, either alone or in
combination with thiazide. Restriction of dietary intake of sodium
and meat will also reduce urinary calcium loss [75], and are
consistent with good nutritional advice anyway; in addition, the
protein restriction may retard the progression of renal failure
once established [76].
Wrong and colleagues have reported successful healing of
rickets in Dent’s disease using “pharmacologic amounts” of
vitamin D, and they recommend “the use of small amounts of
vitamin D or its derivatives” in patients with rickets or osteoma-
lacia [8]. Since therapy with vitamin D will increase urinary
calcium excretion, it would be important to titrate the dose
carefully, following both serum levels of alkaline phosphatase and
urinary calcium excretion.
Those patients who develop end-stage renal failure are often
excellent candidates for transplantation, and also do well on
dialysis. Patients without preexisting rickets do not appear to have
any particular predisposition to renal osteodystrophy, if they are
compliant with conventional therapy.
CONCLUSION
The pace of progress in our knowledge of this disease has been
remarkable. Barely five years from the definition of the syndrome
as X-linked and associated with nephrolithiasis, and before it had
reached wide recognition as a clinical entity, the responsible gene
had been cloned and mutations identified. Much remains to be
done before we can claim to understand the pathophysiology of
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X-linked hypercalciuric nephrolithiasis, but we should look for-
ward to a fuller knowledge of the physiology of this new chloride
channel leading us to a more complete understanding of renal
tubular physiology.
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NOTE ADDED IN PROOF
Two recent reports describe a total of eight mutations in Japanese
patients with LMW proteinuria [80, 81]. Two of these mutations had been
reported previously, and one was another deletion of the entire gene, so
that at present a total of 24 distinct mutations have been reported in 30
families. The new mutations include two missense and three frameshift
mutations. In addition, the report by Akuta, et al. included the first
description of a polymorphism in the CLCN5 gene, with a substitution of
C for T at the third base of codon 484 that leads to no amino acid change.
These patients were young and the phenotype was in general mild, with
several even lacking hypercalciuria. One girl (age 14) had nephrocalcino-
sis, but a CLCN5 mutation was not detected in this patient (Akuta, et al.).
The report by Nakazato, et al. included documentation of a CLCN5
mutation in the families described by Furuse, et al. [24] and discussed
above (in “Other reports”).
A third human disease has now been associated with mutations in a
member of the CLC gene family. Simon and colleagues [82] recently
reported mutations in CLCNKB in a significant subset of patients with
Bartter’s syndrome. This gene encodes the human CLC-Kb chloride
channel, the homolog to the rabbit CLC-Ka channel that is the basolateral
chloride channel in the thick ascending limb. It is very interesting that the
17 kindreds in whom mutations were found included no patients with
nephrocalcinosis, in contrast with patients who have mutations in the
apical bumetanide-sensitive Na-K-2Cl cotransporter or the apical ATP-
sensitive K channel ROMK, in whom nephrocalcinosis does occur. It is
possible that the inactivation of this CLC-Kb channel might protect the
cell from accumulating calcium by depolarizing the membrane, but this is
only speculation.
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